Drugs News and Research

RSS

Results from Bionovo's phase 1B clinical trial of Bezielle published

Bionovo, Inc. announced today the publication of their results from its phase 1B clinical trial of Bezielle (BZL101) for metastatic breast cancer. The results of the study are available online in Breast Cancer Research and Treatment and demonstrate that Bezielle continues to be safe and well tolerated with clinical evidence of anticancer activity in a heavily pretreated population of women diagnosed with metastatic breast cancer.

17 Jan 2010

ALAC to release annual State of Tobacco Control report card for the state of California

American Lung Association in California (ALAC) joined civic leaders, medical professionals and local residents of the city of Richmond to release its annual State of Tobacco Control report card for cities and counties throughout the state of California.

13 Jan 2010

Law enforcement and community activists join hands to support anti-marijuana cause

With President Obama leading the charge against legalization of marijuana in what he calls a "new era of responsibility," a cultural change is taking place in California as more and more community activists join law enforcement officers, former drug addicts and faith-based leaders in support of the anti-marijuana cause.

13 Jan 2010

Era of rapid expansion in biomedical research funding began in 1990's ends

After a decade of remarkable growth, total annual funding for biomedical research in the U.S. has decelerated and may have even fallen when adjusted for inflation. That is the conclusion of a study today published in the Journal of the American Medical Association.

13 Jan 2010

NCCN to present recommendations on REMS in cancer care at Oncology Summit

Risk evaluation and mitigation strategies (REMS), which can be required by the FDA for drugs or biologics with significant toxicity and/or risks, are emerging as a priority topic for a variety of individuals. The goal of REMS to mitigate known or potential drug risks must be balanced with concerns that such programs may be overly complex and burdensome to physicians and other healthcare providers.

13 Jan 2010

Sudden deaths attributed to cocaine use; drug remains a growing health problem in Europe

Forensic pathologists have shown that over three per cent of all sudden deaths in south-west Spain are related to the use of cocaine. They believe their findings can be extrapolated to much of the rest of Europe, indicating that cocaine use is a growing public health problem in Europe and that there is no such thing as "safe" recreational use of small amounts of the drug.

13 Jan 2010

Scripps Research scientists produce chemically complex compound

In 1993 researchers discovered a chemical compound in a sponge off Palau, an island nation in the Pacific Ocean, that has shown anticancer, antibacterial, and antifungal pharmaceutical promise. But that wasn't its greatest allure, at least not for chemists.

13 Jan 2010

ERA-NET PathoGenoMics announces third international joint call for infectious disease research

ERA-NET PathoGenoMics, an initiative of the European Commission aimed at advancing transnational genome-based research programs on human-pathogenic microorganisms, announced today the third international joint call. The third joint call allocated €8.5 Million over 3 years to relevant research projects which will be provided by ERA-NET PathoGenoMics partner organizations from Austria, France, Germany, Hungary, Israel, Portugal, Slovenia and Spain.

13 Jan 2010

Study indicates public and private funding for US biomedical research has decreased substantially

The rate of increase for funding of biomedical research in the U.S. has slowed since 2005, and the level of funding from the National Institutes of Health and industry appears to have decreased by 2 percent in 2008, after adjustment for inflation, according to an article in the January 13 issue of JAMA.

13 Jan 2010

PIMs usage among elderly patients may increase adverse events and health care costs

A new study provides important evidence that the use of certain potentially inappropriate medications (PIMs) among the elderly may increase adverse events and health care costs.

13 Jan 2010

Study: Patients with specific oncogenic rearrangements of ALK gene show greater response to new therapy

Results of a new study in non-small cell lung cancer showed that patients with specific oncogenic rearrangements of the anaplastic lymphoma kinase (ALK) gene within the short arm of chromosome 2 of their tumors had a much greater response to a new therapy - an ALK-inhibitor.

13 Jan 2010

Extended treatment with active ingredient increases bone volume and calcium content

Genta Incorporated today announced publication of two scientific studies that test the active ingredient in Genta’s program to develop orally available gallium-containing compounds and the Company’s marketed product, Ganite® (gallium nitrate for injection).

13 Jan 2010

Pisgah Labs files its eighth patent application for technology to prevent prescription drug abuse

According to the Office of National Drug Control Policy, prescription drug abuse is more prevalent than abuse of cocaine, heroin and methamphetamine. In fact, in the past year, prescription drug abuse ranked second only to marijuana use. In the face of this growing problem, Pisgah Labs, Inc. has just filed its eighth patent application on a technology that promises to curb prescription drug abuse.

13 Jan 2010

University of Leicester study provides new insights into preventer and reliever treatments for asthma

A new study at the University of Leicester is probing why asthma relief inhalers might actually make asthma worse- and what can be done about it.

13 Jan 2010

Synta Pharmaceuticals presents preclinical results of STA-9090 at AACR-IASLC Joint Conference

Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.

13 Jan 2010

NexMed's NexACT technology enhances Taxol's bioavailability through oral administration

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from its research and development group at Bio-Quant successfully demonstrated the ability of the NexACT technology to deliver an oral formulation of Taxol® (paclitaxel) and to enhance the drug’s bioavailability by approximately ten-fold through this oral administration. Taxol, a first line chemotherapy drug used to treat breast, lung and ovarian cancers, is currently administered through an intravenous infusion that can take up to 24 hours to complete.

13 Jan 2010

Majority of doctors appear to ignore FDA warning to screen high-risk medications

A new study concludes that many doctors appear to have largely ignored a Food and Drug Administration warning to screen users of new antipsychotic drugs for high blood sugar and cholesterol, which poses risks to their health and raises questions about the efficacy of warning protocols in general.

13 Jan 2010

ProtoKinetix’ AAGP raises hope for treatment of diabetes

Independent studies done by universities and corporations have illustrated a remarkable increase in the yield of viable stem cells after cryopreservation using AAGP™ in the freeze-thaw process. One future approach to increasing diabetics’ insulin production is related to an ability to convert their stem cells into islet cells for transplantation. The feasibility of this procedure is dependent upon the amount of functioning islet cells that can be derived from the patient’s stem cells. This is where AAGP™ can make a very beneficial contribution.

13 Jan 2010

New clinical study: CeNeRx BioPharma's CXB722 has potential as novel anxiolytic

CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today reported that a new clinical study shows that its investigational compound CXB722 has potential as a novel anxiolytic, demonstrating a significant effect on both endocrine and cardiovascular biomarkers associated with stress.

13 Jan 2010

Studies show naturally-occurring protein in humans restores motor function in rats after a stroke

People with impaired mobility after a stroke soon may have a therapy that restores limb function long after the injury, if a supplemental protein works as well in humans as it does in paralyzed rats.

13 Jan 2010

Drugs News and Research

Results from Bionovo's phase 1B clinical trial of Bezielle published

ALAC to release annual State of Tobacco Control report card for the state of California

Law enforcement and community activists join hands to support anti-marijuana cause

Era of rapid expansion in biomedical research funding began in 1990's ends

NCCN to present recommendations on REMS in cancer care at Oncology Summit

Sudden deaths attributed to cocaine use; drug remains a growing health problem in Europe

Scripps Research scientists produce chemically complex compound

ERA-NET PathoGenoMics announces third international joint call for infectious disease research

Study indicates public and private funding for US biomedical research has decreased substantially

PIMs usage among elderly patients may increase adverse events and health care costs

Study: Patients with specific oncogenic rearrangements of ALK gene show greater response to new therapy

Extended treatment with active ingredient increases bone volume and calcium content

Pisgah Labs files its eighth patent application for technology to prevent prescription drug abuse

University of Leicester study provides new insights into preventer and reliever treatments for asthma

Synta Pharmaceuticals presents preclinical results of STA-9090 at AACR-IASLC Joint Conference

NexMed's NexACT technology enhances Taxol's bioavailability through oral administration

Majority of doctors appear to ignore FDA warning to screen high-risk medications

ProtoKinetix’ AAGP raises hope for treatment of diabetes

New clinical study: CeNeRx BioPharma's CXB722 has potential as novel anxiolytic

Studies show naturally-occurring protein in humans restores motor function in rats after a stroke

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News